stockrow
Friday 6 November 2026
Export MNOV’s income statement to Excel — free account
MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023.
- Revenue
- +240.6%
- EPS
- +28.6%
- Free cash flow
- +16.8%
Quarter to June 2026, against a year earlier
1.46
0.01
+0.69%
Follow MNOV
Alert me
MediciNova, Inc. (MNOV) P/E ratio
MediciNova, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNOV MediciNova, Inc. | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)